| Cat.No. | Name | Information |
|---|---|---|
| M3517 | Lapatinib | Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
| M1802 | Lapatinib Ditosylate | Lapatinib Ditosylate (CAS 388082-78-8) is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). |
| M1749 | Gefitinib | Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
| M5621 | Erlotinib (CP-358774) | Erlotinib (CP-358774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| M1913 | Neratinib | Neratinib (HKI-272) is an orally available, irreversible inhibitor of Her 2 tyrosine kinase. |
| M1850 | WZ4002 | WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
| M1869 | Dacomitinib | Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. |
| M5307 | Afatinib dimaleate | Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. |
| M2424 | AZD9291 (Osimertinib) | Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. |
| M1677 | Afatinib (BIBW 2992) | Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| M42083 | EGFR/BRAFV600E-IN-2 | E07 aptamer is an aptamer that targets human epidermal growth factor receptor (hEGFR). |
| M42082 | EGFR/BRAFV600E-IN-3 | EGFR/BRAFV600E-IN-3 is a EGFR, BRAFV600E and EGFRT790M inhibitor with IC50 value of 57 nM, 68 nM and 9.70 nM. |
| M42081 | SIQ17 | SIQ17 is an EGFR inhibitor that inhibits its activity by occupying the ATP-binding site, with IC50 of 0.62 nM. |
| M42080 | GW583340 dihydrochloride | GW 583340 dihydrochloride is a potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50: 0.01 and 0.014 μM respectively). |
| M42079 | OK2 | OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. |
| M42078 | YK-029A | YK-029A is an orally active inhibitor of mutant EGFR, targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). |
| M42077 | EGFR T790M/L858R-IN-2 | EGFRT790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC50 values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. |
| M42076 | Theliatinib tartrate | Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. |
| M42075 | Ruserontinib | Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity. |
| M42074 | EGFR-IN-82 | EGFR-IN-82 is a potent and orally active EGFR inhibitor with IC50 values of 0.09 and 0.06 nM for EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S, respectively. |
| M40931 | ORM-5029 | ORM-5029 is a HER2/HER3-specific dual-targeted antibody degrader coupling (AnDC) for studies related to HER2-positive breast cancer. |
| M40642 | CH7233163 | CH7233163 is a non-covalent ATP-competitive EGFR- del19 /T790M/C797S inhibitor that can achieve potent inhibitory activity and mutation selection by exploiting multiple interactions with the αC helix conformation of EGFR, with antitumor activity, and can be used in studies related to non-small cell lung cancer (NSCLC). |
| M40640 | BLU-701 | BLU-701 is a highly selective, potent EGFR tyrosine kinase inhibitor (TKI) with activity against EGFR-activating mutations and C797S-resistant mutations for studies related to non-small cell lung cancer (NSCLC). |
| M40638 | BBT-176 | BBT-176 is a novel, EGFR tyrosine kinase inhibitor (TKI) targeting the C797S mutation for studies related to non-small cell lung cancer (NSCLC). |
| M40622 | Firmonertinib | Firmonertinib is an irreversible and selective third-generation EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. It can be used in studies related to non-small cell lung cancer (NSCLC). |
| M40621 | DZD1516 | DZD1516 is an orally active, potent, reversible, and selective HER2 small molecule tyrosine kinase inhibitors (TKIs) with an IC50 value of 0.56 nM, which completely penetrates the blood-brain barrier. It can be used in studies related to HER2-positive breast cancer. |
| M40597 | Ametumumab | Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
| M39005 | Astragaloside VI | Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. |
| M30826 | EAI001 | EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
